Showing 2441-2450 of 5909 results for "".
- Outlook Therapeutics Appoints Surendra Sharma, MD, and Glen Olsheim to Leadership Positionshttps://modernod.com/news/outlook-therapeutics-appoints-surendra-sharma-md-and-glen-olsheim-to-leadership-positions/2481359/Outlook Therapeutics announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence. “Outlook Therapeutics is very happy to welcome Surendra and Glen to our growing executive leadership te
- Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defectshttps://modernod.com/news/trefoil-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-tthx1114-for-treatment-of-corneal-epithelial-defects/2481356/Trefoil Therapeutics announced dosing of the first patient in its phase 1 safety study evaluating TTHX1114 as a topical eye drop formulation designed to reduce the duration and impact of corneal epithelial defects. The phase 1 study is designed to assess t
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Pixium Vision Announces Publications Demonstrating the Potential of the Next Generation PRIMA Implanthttps://modernod.com/news/pixium-vision-announces-publications-demonstrating-the-potential-of-the-next-generation-prima-implant/2481348/Pixium Vision announced that the second generation of implants for its bionic vision system PRIMA for atrophic age-related macular degeneration (AMD) could restore vision at five times higher resolution than the current PRIMA implants, according to a company news release. Pixi
- Market Scope: Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12 Billionhttps://modernod.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/Market Scope forecasts that the global refractive surgery industry will generate $12 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent. The health care research company expects revenue at the manufacturer level to
- Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defect (PCED)https://modernod.com/news/amber-ophthalmics-announces-positive-topline-phase-2-data-evaluating-nexagon-for-the-treatment-of-persistent-corneal-epithelial-defect-pced/2481332/Amber Ophthalmics announced positive topline results from the phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of Nexagon (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (P
- Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2https://modernod.com/news/frontera-therapeutics-doses-first-patient-in-phase-1-clinical-trial-for-gene-therapy-ft-001-for-the-treatment-of-leber-congenital-amaurosis-2/2481327/Frontera Therapeutics announced that it has dosed the first patient in a phase 1 clinical trial of its lead gene therapy program, FT-001, for the treatment of Leber Congenital Amaurosis-2, a severe inherited retinal disease related to a mutation in the RPE65 gene. FT-001 is administered by a
- Alcon Introduces Reusable Toric Lens with Launch of TOTAL30 for Astigmatismhttps://modernod.com/news/alcon-introduces-reusable-toric-lens-with-launch-of-total30-for-astigmatism/2481324/Alcon announced plans to launch TOTAL30 for Astigmatism, which the company calls the first-and-only reusable contact lens with water gradient material for astigmatic contact lens wearers. Using Alcon’s proprietary water gradient material, first introduced with DAILIES TOTAL1&
- Eversight and the Department of Health–Abu Dhabi Partner to Establish UAE’s First Eye and Tissue Bankhttps://modernod.com/news/eversight-and-the-department-of-health-abu-dhabi-partner-to-establish-uaes-first-eye-and-tissue-bank/2481291/Global nonprofit eye bank Eversight and the Department of Health – Abu Dhabi (DoH) are partnering to establish the first eye and tissue bank in the United Arab Emirates (UAE). The
- Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue Hydration Boost Contact Lens Rehydrating Dropshttps://modernod.com/news/bausch-lomb-receives-510k-clearance-from-fda-for-biotrue-hydration-boost-contact-lens-rehydrating-drops/2481290/Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. “We ar